CRISPR THERAPTC (NASDAQ: CRSP) and AC Immune SA (NASDAQ:ACIU) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Earnings & Valuation

This table compares CRISPR THERAPTC and AC Immune SA’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
CRISPR THERAPTC $10.18 million 76.96 -$79.90 million ($3.47) -5.56
AC Immune SA $5.83 million 110.18 -$34.66 million N/A N/A

AC Immune SA has higher revenue, but lower earnings than CRISPR THERAPTC.


This table compares CRISPR THERAPTC and AC Immune SA’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CRISPR THERAPTC -406.61% -47.46% -22.13%
AC Immune SA N/A N/A N/A

Institutional & Insider Ownership

23.9% of CRISPR THERAPTC shares are owned by institutional investors. Comparatively, 18.1% of AC Immune SA shares are owned by institutional investors. 40.0% of CRISPR THERAPTC shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for CRISPR THERAPTC and AC Immune SA, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISPR THERAPTC 0 4 4 0 2.50
AC Immune SA 0 0 3 0 3.00

CRISPR THERAPTC presently has a consensus price target of $23.08, suggesting a potential upside of 19.60%. AC Immune SA has a consensus price target of $21.67, suggesting a potential upside of 92.42%. Given AC Immune SA’s stronger consensus rating and higher probable upside, analysts clearly believe AC Immune SA is more favorable than CRISPR THERAPTC.


AC Immune SA beats CRISPR THERAPTC on 7 of the 11 factors compared between the two stocks.


Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.

About AC Immune SA

AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn, among others.

Receive News & Ratings for CRISPR THERAPTC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR THERAPTC and related companies with Analyst Ratings Network's FREE daily email newsletter.